Cargando…
Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts
Duchenne muscular dystrophy (DMD) affects myofibers and muscle stem cells, causing progressive muscle degeneration and repair defects. It was unknown whether dystrophic myoblasts—the effector cells of muscle growth and regeneration—are affected. Using transcriptomic, genome-scale metabolic modelling...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514850/ https://www.ncbi.nlm.nih.gov/pubmed/36164827 http://dx.doi.org/10.7554/eLife.75521 |
_version_ | 1784798360095424512 |
---|---|
author | Gosselin, Maxime RF Mournetas, Virginie Borczyk, Malgorzata Verma, Suraj Occhipinti, Annalisa Róg, Justyna Bozycki, Lukasz Korostynski, Michal Robson, Samuel C Angione, Claudio Pinset, Christian Gorecki, Dariusz C |
author_facet | Gosselin, Maxime RF Mournetas, Virginie Borczyk, Malgorzata Verma, Suraj Occhipinti, Annalisa Róg, Justyna Bozycki, Lukasz Korostynski, Michal Robson, Samuel C Angione, Claudio Pinset, Christian Gorecki, Dariusz C |
author_sort | Gosselin, Maxime RF |
collection | PubMed |
description | Duchenne muscular dystrophy (DMD) affects myofibers and muscle stem cells, causing progressive muscle degeneration and repair defects. It was unknown whether dystrophic myoblasts—the effector cells of muscle growth and regeneration—are affected. Using transcriptomic, genome-scale metabolic modelling and functional analyses, we demonstrate, for the first time, convergent abnormalities in primary mouse and human dystrophic myoblasts. In Dmd(mdx) myoblasts lacking full-length dystrophin, the expression of 170 genes was significantly altered. Myod1 and key genes controlled by MyoD (Myog, Mymk, Mymx, epigenetic regulators, ECM interactors, calcium signalling and fibrosis genes) were significantly downregulated. Gene ontology analysis indicated enrichment in genes involved in muscle development and function. Functionally, we found increased myoblast proliferation, reduced chemotaxis and accelerated differentiation, which are all essential for myoregeneration. The defects were caused by the loss of expression of full-length dystrophin, as similar and not exacerbated alterations were observed in dystrophin-null Dmd(mdx-βgeo) myoblasts. Corresponding abnormalities were identified in human DMD primary myoblasts and a dystrophic mouse muscle cell line, confirming the cross-species and cell-autonomous nature of these defects. The genome-scale metabolic analysis in human DMD myoblasts showed alterations in the rate of glycolysis/gluconeogenesis, leukotriene metabolism, and mitochondrial beta-oxidation of various fatty acids. These results reveal the disease continuum: DMD defects in satellite cells, the myoblast dysfunction affecting muscle regeneration, which is insufficient to counteract muscle loss due to myofiber instability. Contrary to the established belief, our data demonstrate that DMD abnormalities occur in myoblasts, making these cells a novel therapeutic target for the treatment of this lethal disease. |
format | Online Article Text |
id | pubmed-9514850 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | eLife Sciences Publications, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-95148502022-09-28 Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts Gosselin, Maxime RF Mournetas, Virginie Borczyk, Malgorzata Verma, Suraj Occhipinti, Annalisa Róg, Justyna Bozycki, Lukasz Korostynski, Michal Robson, Samuel C Angione, Claudio Pinset, Christian Gorecki, Dariusz C eLife Medicine Duchenne muscular dystrophy (DMD) affects myofibers and muscle stem cells, causing progressive muscle degeneration and repair defects. It was unknown whether dystrophic myoblasts—the effector cells of muscle growth and regeneration—are affected. Using transcriptomic, genome-scale metabolic modelling and functional analyses, we demonstrate, for the first time, convergent abnormalities in primary mouse and human dystrophic myoblasts. In Dmd(mdx) myoblasts lacking full-length dystrophin, the expression of 170 genes was significantly altered. Myod1 and key genes controlled by MyoD (Myog, Mymk, Mymx, epigenetic regulators, ECM interactors, calcium signalling and fibrosis genes) were significantly downregulated. Gene ontology analysis indicated enrichment in genes involved in muscle development and function. Functionally, we found increased myoblast proliferation, reduced chemotaxis and accelerated differentiation, which are all essential for myoregeneration. The defects were caused by the loss of expression of full-length dystrophin, as similar and not exacerbated alterations were observed in dystrophin-null Dmd(mdx-βgeo) myoblasts. Corresponding abnormalities were identified in human DMD primary myoblasts and a dystrophic mouse muscle cell line, confirming the cross-species and cell-autonomous nature of these defects. The genome-scale metabolic analysis in human DMD myoblasts showed alterations in the rate of glycolysis/gluconeogenesis, leukotriene metabolism, and mitochondrial beta-oxidation of various fatty acids. These results reveal the disease continuum: DMD defects in satellite cells, the myoblast dysfunction affecting muscle regeneration, which is insufficient to counteract muscle loss due to myofiber instability. Contrary to the established belief, our data demonstrate that DMD abnormalities occur in myoblasts, making these cells a novel therapeutic target for the treatment of this lethal disease. eLife Sciences Publications, Ltd 2022-09-27 /pmc/articles/PMC9514850/ /pubmed/36164827 http://dx.doi.org/10.7554/eLife.75521 Text en © 2022, Gosselin et al https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Medicine Gosselin, Maxime RF Mournetas, Virginie Borczyk, Malgorzata Verma, Suraj Occhipinti, Annalisa Róg, Justyna Bozycki, Lukasz Korostynski, Michal Robson, Samuel C Angione, Claudio Pinset, Christian Gorecki, Dariusz C Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts |
title | Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts |
title_full | Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts |
title_fullStr | Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts |
title_full_unstemmed | Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts |
title_short | Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts |
title_sort | loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514850/ https://www.ncbi.nlm.nih.gov/pubmed/36164827 http://dx.doi.org/10.7554/eLife.75521 |
work_keys_str_mv | AT gosselinmaximerf lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts AT mournetasvirginie lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts AT borczykmalgorzata lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts AT vermasuraj lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts AT occhipintiannalisa lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts AT rogjustyna lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts AT bozyckilukasz lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts AT korostynskimichal lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts AT robsonsamuelc lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts AT angioneclaudio lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts AT pinsetchristian lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts AT goreckidariuszc lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts |